Abbott Laboratories (ABT) operating KPIs
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — International Revenue ($M) ($M)
Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — International Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 367 | -1.1% | SEC Filing (0001628280-26-002982) ↗ |
| FY2024 | Dec 31, 2024 | 371 | -7.7% | SEC Filing (0001628280-25-002092) ↗ |
| FY2023 | Dec 31, 2023 | 402 | -35.7% | SEC Filing (0001628280-25-002092) ↗ |
| FY2022 | Dec 31, 2022 | 625 | -27.4% | SEC Filing (0001628280-24-002009) ↗ |
| FY2021 | Dec 31, 2021 | 861 | +5.4% | SEC Filing (0001628280-23-001516) ↗ |
| FY2020 | Dec 31, 2020 | 817 | +178.8% | SEC Filing (0001104659-21-007942) ↗ |
| FY2019 | Dec 31, 2019 | 293 | -11.7% | SEC Filing (0001104659-20-005717) ↗ |
| FY2018 | Dec 31, 2018 | 332 | +9.6% | SEC Filing (0001104659-19-002848) ↗ |
| FY2017 | Dec 31, 2017 | 303 | +11.4% | SEC Filing (0001104659-18-003691) ↗ |
| FY2016 | Dec 31, 2016 | 272 | -1.1% | SEC Filing (0001104659-17-003920) ↗ |
| FY2015 | Dec 31, 2015 | 275 | – | SEC Filing (0001104659-16-091861) ↗ |
Breakdown
What makes up molecular diagnostics (legacy standalone subsegment through fy2025q4 — alinity m) — international revenue ($m)
Cite this data
StockData. (2026). Abbott Laboratories Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — International Revenue ($M) ($M), annual FY2015–FY2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/dx-mol-leg-rev-intl
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.